Investors and analysts can register for the event through the company's official investor relations portal. Participants from North America and Canada may also join via the toll-free dial-in line at 1-800-836-8184. Management suggests connecting at least 10 minutes before the scheduled start time to ensure connectivity. The company will maintain an archived version of the webcast on its website for 30 days following the presentation.

ADC Therapeutics continues to focus on its CD19-directed antibody drug conjugate, ZYNLONTA, which currently holds FDA accelerated approval and European Commission conditional approval for treating relapsed or refractory diffuse large B-cell lymphoma. Beyond its current market footprint, the firm is actively evaluating the drug's efficacy in combination therapies and earlier lines of treatment as it manages operations across Switzerland and New Jersey.